Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

QIAGEN

BATS-CHIXE:QIAD
Snowflake Description

Reasonable growth potential with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
QIAD
BATS-CHIXE
$9B
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The last earnings update was 29 days ago. More info.


Add to Portfolio Compare Print
QIAD Share Price and Events
7 Day Returns
0.3%
BATS-CHIXE:QIAD
19.9%
GB Life Sciences
10%
GB Market
1 Year Returns
-0.1%
BATS-CHIXE:QIAD
-15.8%
GB Life Sciences
-23%
GB Market
QIAD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
QIAGEN (QIAD) 0.3% 10.7% 20.6% -0.1% 35.7% 49.3%
GB Life Sciences 19.9% -20.4% -32% -15.8% -16.1% -24.9%
GB Market 10% -17.6% -27.3% -23% -24.2% -21.8%
1 Year Return vs Industry and Market
  • QIAD outperformed the Life Sciences industry which returned -15.8% over the past year.
  • QIAD outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23% over the past year.
Price Volatility
QIAD
Industry
5yr Volatility vs Market

Value

 Is QIAGEN undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of QIAGEN to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for QIAGEN.

BATS-CHIXE:QIAD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 17 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.6%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:QIAD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 5.4%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.03
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.033 (1 + (1- 25%) (19.22%))
1.122
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.12
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (1.122 * 5.44%)
6.63%

Discounted Cash Flow Calculation for BATS-CHIXE:QIAD using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for QIAGEN is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:QIAD DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.63%)
2020 303.26 Analyst x8 284.39
2021 361.42 Analyst x8 317.86
2022 400.73 Analyst x4 330.51
2023 428.01 Est @ 6.81% 331.05
2024 449.09 Est @ 4.92% 325.75
2025 465.28 Est @ 3.61% 316.50
2026 477.76 Est @ 2.68% 304.78
2027 487.49 Est @ 2.04% 291.64
2028 495.22 Est @ 1.58% 277.84
2029 501.50 Est @ 1.27% 263.86
Present value of next 10 years cash flows $3,044.00
BATS-CHIXE:QIAD DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $501.50 × (1 + 0.53%) ÷ (6.63% – 0.53%)
$8,261.39
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $8,261.39 ÷ (1 + 6.63%)10
$4,346.63
BATS-CHIXE:QIAD Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $3,044.00 + $4,346.63
$7,390.63
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $7,390.63 / 227.63
$32.47
BATS-CHIXE:QIAD Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:QIAD represents 0.90351x of NYSE:QGEN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.90351x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 32.47 x 0.90351
€29.34
Value per share (EUR) From above. €29.34
Current discount Discount to share price of €36.57
= -1 x (€36.57 - €29.34) / €29.34
-24.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of QIAGEN is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for QIAGEN's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are QIAGEN's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:QIAD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.18
NYSE:QGEN Share Price ** NYSE (2020-03-30) in USD $40.47
Europe Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 48.4x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 747 Publicly-Listed Companies 12.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of QIAGEN.

BATS-CHIXE:QIAD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:QGEN Share Price ÷ EPS (both in USD)

= 40.47 ÷ -0.18

-221.39x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • QIAGEN is loss making, we can't compare its value to the Europe Life Sciences industry average.
  • QIAGEN is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does QIAGEN's expected growth come at a high price?
Raw Data
BATS-CHIXE:QIAD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -221.39x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts
34.2%per year
Europe Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 2.05x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 526 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for QIAGEN, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on QIAGEN's assets?
Raw Data
BATS-CHIXE:QIAD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $11.14
NYSE:QGEN Share Price * NYSE (2020-03-30) in USD $40.47
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry PB Ratio Median Figure of 13 Publicly-Listed Life Sciences Companies 1.88x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,322 Publicly-Listed Companies 1.08x
BATS-CHIXE:QIAD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:QGEN Share Price ÷ Book Value per Share (both in USD)

= 40.47 ÷ 11.14

3.63x

* Primary Listing of QIAGEN.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • QIAGEN is overvalued based on assets compared to the GB Life Sciences industry average.
X
Value checks
We assess QIAGEN's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. QIAGEN has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is QIAGEN expected to perform in the next 1 to 3 years based on estimates from 17 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
34.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is QIAGEN expected to grow at an attractive rate?
  • QIAGEN's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • QIAGEN's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • QIAGEN's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:QIAD Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:QIAD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts 34.2%
BATS-CHIXE:QIAD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 17 Analysts 5.4%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 43.5%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average -10.3%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:QIAD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:QIAD Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 2,006 747 438 5
2023-12-31 1,881 670 387 5
2022-12-31 1,778 592 316 10
2021-12-31 1,674 503 270 16
2020-12-31 1,570 434 234 17
2020-03-31
BATS-CHIXE:QIAD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 1,526 331 -41
2019-09-30 1,516 332 -25
2019-06-30 1,511 320 196
2019-03-31 1,507 356 188
2018-12-31 1,502 359 190
2018-09-30 1,496 325 90
2018-06-30 1,482 324 78
2018-03-31 1,453 275 55
2017-12-31 1,418 287 40
2017-09-30 1,387 311 89
2017-06-30 1,362 323 75
2017-03-31 1,347 353 82

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • QIAGEN's earnings are expected to grow significantly at over 20% yearly.
  • QIAGEN's revenue is expected to grow by 5.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:QIAD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below

All data from QIAGEN Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:QIAD Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 1.64 1.94 1.33 2.00
2023-12-31 1.65 1.75 1.54 2.00
2022-12-31 1.49 1.73 1.29 4.00
2021-12-31 1.21 1.45 0.85 7.00
2020-12-31 1.03 1.10 0.87 7.00
2020-03-31
BATS-CHIXE:QIAD Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.18
2019-09-30 -0.11
2019-06-30 0.86
2019-03-31 0.83
2018-12-31 0.84
2018-09-30 0.40
2018-06-30 0.34
2018-03-31 0.24
2017-12-31 0.18
2017-09-30 0.39
2017-06-30 0.33
2017-03-31 0.36

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • QIAGEN is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess QIAGEN's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
QIAGEN has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has QIAGEN performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare QIAGEN's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • QIAGEN does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare QIAGEN's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare QIAGEN's 1-year growth to the Europe Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
QIAGEN's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from QIAGEN Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:QIAD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1,526.42 -41.46 530.11 157.45
2019-09-30 1,516.13 -25.44 540.21 164.13
2019-06-30 1,511.35 195.52 527.48 164.31
2019-03-31 1,506.93 187.61 520.73 163.12
2018-12-31 1,501.85 190.38 496.85 161.85
2018-09-30 1,495.54 89.74 475.91 162.13
2018-06-30 1,481.60 77.90 473.82 158.40
2018-03-31 1,453.40 55.04 465.85 156.67
2017-12-31 1,417.54 40.39 477.64 154.08
2017-09-30 1,387.19 88.71 466.52 145.36
2017-06-30 1,361.90 75.03 479.58 143.10
2017-03-31 1,347.32 82.34 480.19 147.20
2016-12-31 1,337.99 80.40 469.60 149.84
2016-09-30 1,320.02 123.40 484.98 156.98
2016-06-30 1,295.89 122.53 471.41 156.51
2016-03-31 1,280.94 126.37 450.00 148.08
2015-12-31 1,280.99 130.15 444.66 146.83
2015-09-30 1,292.86 104.37 474.91 151.39
2015-06-30 1,314.75 105.13 483.73 157.29
2015-03-31 1,326.13 112.86 487.34 161.62
2014-12-31 1,344.78 116.37 490.08 163.67
2014-09-30 1,345.45 150.94 487.40 163.50
2014-06-30 1,331.11 156.95 487.42 156.38
2014-03-31 1,315.48 72.36 486.52 152.11
2013-12-31 1,301.98 69.07 486.10 146.07
2013-09-30 1,287.43 44.03 497.86 111.81
2013-06-30 1,269.61 32.49 512.22 108.48

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if QIAGEN has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • QIAGEN used its assets less efficiently than the Europe Life Sciences industry average last year based on Return on Assets.
  • It is difficult to establish if QIAGEN improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess QIAGEN's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
QIAGEN has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is QIAGEN's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up QIAGEN's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • QIAGEN is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • QIAGEN's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of QIAGEN's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from QIAGEN Company Filings, last reported 3 months ago.

BATS-CHIXE:QIAD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 2,536.59 1,712.38 753.23
2019-09-30 2,467.44 1,761.83 799.19
2019-06-30 2,632.39 1,777.51 785.96
2019-03-31 2,606.06 1,760.95 780.39
2018-12-31 2,634.97 2,192.97 1,393.69
2018-09-30 2,527.30 1,793.32 920.73
2018-06-30 2,523.86 1,792.19 900.19
2018-03-31 2,580.54 1,814.78 1,014.19
2017-12-31 2,541.00 1,787.36 1,016.91
2017-09-30 2,566.60 1,769.99 974.95
2017-06-30 2,505.37 1,396.33 608.85
2017-03-31 2,429.80 1,071.56 273.39
2016-12-31 2,607.10 1,067.10 532.18
2016-09-30 2,665.70 1,075.84 464.34
2016-06-30 2,626.51 1,072.41 406.44
2016-03-31 2,624.60 1,070.89 447.26
2015-12-31 2,568.07 1,049.03 420.83
2015-09-30 2,520.28 1,058.91 429.53
2015-06-30 2,537.44 1,049.59 367.55
2015-03-31 2,478.74 1,048.97 392.29
2014-12-31 2,658.00 1,172.08 576.70
2014-09-30 2,713.67 1,164.38 692.02
2014-06-30 2,754.78 1,175.36 654.77
2014-03-31 2,732.59 1,171.30 677.97
2013-12-31 2,723.87 845.48 380.23
2013-09-30 2,676.24 846.66 355.75
2013-06-30 2,595.30 846.36 373.20
  • QIAGEN's level of debt (67.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (43.8% vs 67.5% today).
  • Debt is not well covered by operating cash flow (19.3%, less than 20% of total debt).
  • QIAGEN is making a loss, therefore interest payments are not well covered by earnings.
X
Financial health checks
We assess QIAGEN's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. QIAGEN has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is QIAGEN's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from QIAGEN dividends. Estimated to be 0% next year.
If you bought €2,000 of QIAGEN shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate QIAGEN's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate QIAGEN's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:QIAD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 12 Stocks 0.7%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 629 Stocks 6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.4%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.7%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:QIAD Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 2.00
2021-12-31 0.00 3.00
2020-12-31 0.00 3.00
2020-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as QIAGEN has not reported any payouts.
  • Unable to verify if QIAGEN's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of QIAGEN's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as QIAGEN has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of QIAGEN's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.
X
Income/ dividend checks
We assess QIAGEN's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can QIAGEN afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. QIAGEN has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of QIAGEN's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Thierry Bernard
COMPENSATION $1,307,869
AGE 54
TENURE AS CEO 0.4 years
CEO Bio

Mr. Thierry Bernard has been Chief Executive Officer of QIAGEN N.V. since March 2020. He served as Interim Chief Executive Officer of Qiagen NV since October 2019 until March 2020. He has been a Senior Vice President of Molecular Diagnostics Business Area at Qiagen NV since February 2015. Mr. Bernard leads QIAGEN’s growing presence in diagnostic solutions for healthcare. He joined the QIAGEN team in February 2015 from bioMérieux, where he served in roles of increasing responsibility for 15 years. He served as Chief Executive Officer of Daktari Diagnostics. He served as Corporate Vice-President of Global Commercial Operations & Investor Relations and Executive Vice President of Greater China at bioMérieux SA. From 2007 to 2012, Mr. Bernard held the role of Senior Executive Vice President of Global Commercial Operations, Sales, Marketing, Customer Service & Investor Relations out of Boston. Mr. Bernard served as Corporate Vice President of Asia Pacific Region at bioMérieux SA. He served as a Executive Vice President of Greater China and Corporate Vice-President of Global Commercial Operations & Investor Relations at bioMérieux, Inc. Mr. Bernard served as Corporate Vice President of Global Commercial Operations at bioMérieux SA. Mr. Bernard served as Corporate Vice President of Europe, Middle East, Africa at bioMérieux SA. Mr. Bernard joined bioMérieux in 1999, as Strategy Director and served as Head of Strategy & Clinical Marketing from 1999 to 2002. In 2002, he assumed responsibility for the Europe / Middle East / Africa zone. He served as a Director of AdvanDx, HepatoChem and Daktari Diagnostics, Inc. He is a graduate of Sciences Po (Paris), and has a Master in Economy and Administration from the College of Europe and a Master of Science from the London School of Economics. He has a degree in Foreign Trade (Barcelona) and is one of France's Foreign Trade Advisors (Conseiller du Commerce Extérieur de la France).

CEO Compensation
  • Insufficient data for Thierry to compare compensation growth.
  • Thierry's remuneration is lower than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the QIAGEN management team in years:

2.2
Average Tenure
53.5
Average Age
  • The tenure for the QIAGEN management team is about average.
Management Team

Thierry Bernard

TITLE
Chief Executive Officer
COMPENSATION
$1M
AGE
54
TENURE
0.4 yrs

Roland Sackers

TITLE
CFO, MD & Member of Management Board
COMPENSATION
$1M
AGE
50
TENURE
16.2 yrs

Peer Schatz

TITLE
Senior Advisor
COMPENSATION
$8M
AGE
53
TENURE
0.4 yrs

Barthold Piening

TITLE
Senior VP & Head of Global Operations
AGE
61
TENURE
1.3 yrs

John Gilardi

TITLE
Vice President of Corporate Communications & Investor Relations
TENURE
9.4 yrs

Jean-Pascal Viola

TITLE
Head of Corporate Business Development
TENURE
4.8 yrs

Stephany Foster

TITLE
SVP & Head of Human Resources
TENURE
0.4 yrs

Thomas Schweins

TITLE
Senior Vice President of Life Science Business Area
TENURE
2.2 yrs

Jonathan Sheldon

TITLE
Senior Vice President of Qiagen Digital Insights Business Area
TENURE
2.2 yrs

Thomas Neidert

TITLE
Vice President of Global Treasury
Board of Directors Tenure

Average tenure and age of the QIAGEN board of directors in years:

6.7
Average Tenure
62.5
Average Age
  • The tenure for the QIAGEN board of directors is about average.
Board of Directors

Sven Björklund

TITLE
Independent Supervisory Board Chairman
COMPENSATION
$173K
AGE
63
TENURE
1.7 yrs

Liz Tallett

TITLE
Independent Supervisory Director
COMPENSATION
$97K
AGE
69
TENURE
8.7 yrs

Larry Rosen

TITLE
Independent Supervisory Director
COMPENSATION
$83K
AGE
62
TENURE
6.7 yrs

Metin Colpan

TITLE
Independent Supervisory Director
COMPENSATION
$76K
AGE
64
TENURE
16.2 yrs

Stéphane Bancel

TITLE
Independent Supervisory Director
COMPENSATION
$90K
AGE
46
TENURE
6.7 yrs

Elaine Mardis

TITLE
Independent Supervisory Director
COMPENSATION
$64K
AGE
56
TENURE
5.7 yrs
Who owns this company?
Recent Insider Trading
  • QIAGEN individual insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Mar 20 Sell Roland Sackers Individual 20. Mar 20 20. Mar 20 -77,379 €20.79 €-1,565,986
20. Mar 20 Buy Roland Sackers Individual 20. Mar 20 20. Mar 20 77,379 €36.04 €2,786,251
04. Mar 20 Sell Lawrence Rosen Individual 04. Mar 20 04. Mar 20 -5,553 €37.29 €-207,089
X
Management checks
We assess QIAGEN's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. QIAGEN has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels (DNA and RNA), library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc., CLIA-certified laboratories, and NuProbe Global. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Details
Name: QIAGEN N.V.
QIAD
Exchange: BATS-CHIXE
Founded: 1986
$8,349,814,481
227,626,974
Website: http://www.qiagen.com
Address: QIAGEN N.V.
Hulsterweg 82,
Venlo,
Limburg, 5912 PL,
Netherlands
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE QGEN Common Shares New York Stock Exchange US USD 28. Jun 1996
DB QIA Common Shares Deutsche Boerse AG DE EUR 28. Jun 1996
XTRA QIA Common Shares XETRA Trading Platform DE EUR 28. Jun 1996
LSE 0RLT Common Shares London Stock Exchange GB EUR 28. Jun 1996
SWX QGEN Common Shares SIX Swiss Exchange CH CHF 28. Jun 1996
WBAG QGEN Common Shares Wiener Boerse AG AT EUR 28. Jun 1996
ETLX QIA Common Shares Eurotlx IT EUR 28. Jun 1996
BATS-CHIXE QIAD Common Shares BATS 'Chi-X Europe' GB EUR 28. Jun 1996
Number of employees
Current staff
Staff numbers
5,096
QIAGEN employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 19:38
End of day share price update: 2020/03/30 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.